A new facility at The University of Queensland (UQ) is set to provide Australian researchers with cancer vaccines tailored to individual patients.
The lab at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will combine equipment and expertise to enable the design, manufacture, and delivery of new mRNA cancer vaccines.
Backed by a $3.3 million grant from the Medical Research Future Fund’s ³Ô¹ÏÍøÕ¾ Critical Research Infrastructure program, the new hub will provide the local research community with vaccines that match each patient’s specific treatment needs.
Dr Seth Cheetham, Deputy Director of AIBN’s BASE facility, said it could transform cancer treatment.
“Personalised mRNA cancer vaccines are now being used to train the body’s immune system to recognise and eradicate cancer cells,” said Dr Cheetham.
“Despite the huge potential, Australian researchers haven’t had the necessary infrastructure to build these vaccines, leading to a critical gap in the local drug development pipeline.
“This lab changes that, with a leading team of investigators in a purpose-built space, working with local industry and academics to progress a range of high-quality mRNA cancer vaccine candidates from design through to preclinical evaluation, with the aim of enabling future clinical trials.”
The mRNA cancer vaccine hub is expected to operate in BASE by late 2024.
BASE is already recognised as Australia’s leading provider of mRNA for research and pilot studies. Since its launch in 2021, it has provided academic and industry partners with more than 300 experimental-grade vaccines.
“As well as the potential impacts on patient health, mRNA cancer vaccines represent a $7 billion opportunity over the next decade,” said Dr Cheetham.
“This is a rapidly expanding industry encompassing researchers, biotech start-ups and multinational pharmaceuticals, and AIBN and BASE will now be at the centre of a range of promising new treatment options.”
AIBN director Professor Alan Rowan said the hub would complement Australia’s existing research strengths in oncology and affirm AIBN as a therapeutics and personalised medicine pipeline.
“Governments and society want sustainable innovation that enables high quality research and delivers translatable outcomes,” said Professor Rowan.
“The mRNA cancer vaccine hub is the latest example of how AIBN combines world class infrastructure and technical expertise to bridge the gap between research and clinical development.”
